National Health Investors (NHI) came out with quarterly funds from operations (FFO) of $1.10 per share, missing the Zacks Consensus Estimate of $1.17 per share. This compares to FFO of $1.24 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an FFO surprise of -5.98%. A quarter ago, it was expected that this health care real estate investment trust would post FFO of $1.05 per share when it actually produced FFO of $1.06, delivering a surprise of 0.95%.
Over the last four quarters, the company has surpassed consensus FFO estimates just once.
National Health Investors , which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $71.33 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 1.28%. This compares to year-ago revenues of $80.89 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.
National Health Investors shares have lost about 6.4% since the beginning of the year versus the S&P 500's decline of -13.5%.
What's Next for National Health Investors?
While National Health Investors has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.
Ahead of this earnings release, the estimate revisions trend for National Health Investors: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus FFO estimate is $1.14 on $73.14 million in revenues for the coming quarter and $4.42 on $278.37 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Gladstone Land (LAND), another stock in the same industry, has yet to report results for the quarter ended March 2022. The results are expected to be released on May 10.
This real estate investment trust specializing in farmland is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +5.9%. The consensus EPS estimate for the quarter has been revised 2% higher over the last 30 days to the current level.
Gladstone Land's revenues are expected to be $20.35 million, up 27% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
National Health Investors, Inc. (NHI) : Free Stock Analysis Report
Gladstone Land Corporation (LAND) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research